Skip to content
Home
The Guideline
2023 Update: Summary of changes to Recommendations
Summary of Recommendations
Section 1: Background, aims and concise methods
1.1 Summary
1.2 Introduction
1.3 Molecular Mechanisms Of Action Of SGLT2I Inhibition
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
1.5 Guideline Aims & Development
1.6 References
Section 2: SGLT-2 inhibition and kidney protection in people with CKD in the context of type 2 diabetes mellitus
2.1 Background
2.2 Recommendations For Use
2.3 Clinical Research Recommendations
2.4 Recommendations For Implementation
2.5 Audit Measures
2.6 References
Section 3: SGLT-2 inhibition and kidney protection in people with CKD without diabetes mellitus
3.1 Background
3.2 Recommendations For Use
3.3 Clinical Research Recommendations
3.4 Recommendations for Implementation
3.5 Audit Measures
3.6 References
Section 4: Selection of SGLT-2 inhibitors
4.1 Background
4.2 Current Licensed Indications for SGLT-2 Inhibitor Use
4.3 References
Section 5: Prescribing SGLT-2 inhibitors safely
5.0 Background
5a. Diabetic ketoacidosis
5b. Hypoglycaemia
5c. Acute Kidney Injury, Hypovolaemia and Potassium
5d. Peripheral vascular disease and amputation risk
5e. Fracture risk
5f. Multimorbidity and frailty
5g. Mycotic genital infections and Fournier’s gangrene
5h. Urinary tract infections
5i. Children, pregnancy and breast feeding
5.1 References
Section 6: Lay summaries and patient information leaflets
6.0 Background
6.1 Lay Executive Summary
6.2 Full Summary of Guideline
6.3 Patient Information Leaflet on SGLT2 inhibitors
Section 7: Use in special populations of specific interest
7a. Type 1 diabetes mellitus (DM)
7b. Kidney transplant recipients
7c. Acute decompensated heart failure
7.1 References
List of Abbreviations
Appendix
Appendix I: Systematic literature review design and results
Appendix II: Revision history
Appendix III: Working group membership affiliations
For Patients
About Us
Contact Us
Facebook
Twitter
Youtube
Linkedin
Home
The Guideline
2023 Update: Summary of changes to Recommendations
Summary of Recommendations
Section 1: Background, aims and concise methods
1.1 Summary
1.2 Introduction
1.3 Molecular Mechanisms Of Action Of SGLT2I Inhibition
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
1.5 Guideline Aims & Development
1.6 References
Section 2: SGLT-2 inhibition and kidney protection in people with CKD in the context of type 2 diabetes mellitus
2.1 Background
2.2 Recommendations For Use
2.3 Clinical Research Recommendations
2.4 Recommendations For Implementation
2.5 Audit Measures
2.6 References
Section 3: SGLT-2 inhibition and kidney protection in people with CKD without diabetes mellitus
3.1 Background
3.2 Recommendations For Use
3.3 Clinical Research Recommendations
3.4 Recommendations for Implementation
3.5 Audit Measures
3.6 References
Section 4: Selection of SGLT-2 inhibitors
4.1 Background
4.2 Current Licensed Indications for SGLT-2 Inhibitor Use
4.3 References
Section 5: Prescribing SGLT-2 inhibitors safely
5.0 Background
5a. Diabetic ketoacidosis
5b. Hypoglycaemia
5c. Acute Kidney Injury, Hypovolaemia and Potassium
5d. Peripheral vascular disease and amputation risk
5e. Fracture risk
5f. Multimorbidity and frailty
5g. Mycotic genital infections and Fournier’s gangrene
5h. Urinary tract infections
5i. Children, pregnancy and breast feeding
5.1 References
Section 6: Lay summaries and patient information leaflets
6.0 Background
6.1 Lay Executive Summary
6.2 Full Summary of Guideline
6.3 Patient Information Leaflet on SGLT2 inhibitors
Section 7: Use in special populations of specific interest
7a. Type 1 diabetes mellitus (DM)
7b. Kidney transplant recipients
7c. Acute decompensated heart failure
7.1 References
List of Abbreviations
Appendix
Appendix I: Systematic literature review design and results
Appendix II: Revision history
Appendix III: Working group membership affiliations
For Patients
About Us
Contact Us
Navigate to sections
2023 Update: Summary of changes to Recommendations
Executive Summary
Quick Reference Guide
Section 1: Background, aims and concise methods
1. Overview
1.1 Summary
1.2 Introduction
1.3 Molecular Mechanisms Of Action Of SGLT2I Inhibition
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
1.5 Guideline Aims & Development
1.6 References
Section 2: SGLT-2 inhibition and renal protection in people with CKD in the context of type 2 diabetes mellitus
2. Overview
2.1 Background
2.2 Recommendations For Use
2.3 Clinical Research Recommendations
2.4 Recommendations For Implementation
2.5 Audit Measures
2.6 References
Section 3: SGLT-2 inhibition and renal protection in people with CKD without diabetes mellitus
3. Overview
3.1 Background
3.2 Recommendations For Use
3.3 Clinical Research Recommendations
3.4 Recommendations for Implementation
3.5 Audit Measures
3.6 References
Section 4: Selection of SGLT-2 inhibitors
4. Overview
4.1 Background
4.2 Current Licensed Indications for SGLT-2 Inhibitor Use
4.3 References
Section 5: Prescribing SGLT-2 inhibitors safely
5. Overview
5.0 Background
5a. Diabetic ketoacidosis
5b. Hypoglycaemia
5c. Acute Kidney Injury, Hypovolaemia and Potassium
5d. Peripheral vascular disease and amputation risk
5e. Fracture risk
5f. Multimorbidity and frailty
5g. Mycotic genital infections and Fournier’s gangrene
5h. Urinary tract infections
5i. Children, pregnancy and breast feeding
5.1 References
Section 6: Lay summaries and patient information leaflets
6. Overview
6.0 Background
6.1 Lay Executive Summary
6.2 Full Summary of Guideline
6.3 Example Patient Information Sheet for a Person being Initiated on an SGLT-2 Inhibitor who also has Diabetes
6.4 Example Patient Information Sheet for a Patient being Initiated on an SGLT-2 Inhibitor who does not have Diabetes
Section 7: Use in special populations of specific interest
7. Overview
7a. Type 1 diabetes mellitus (DM)
7b. Kidney transplant recipients
7c. Acute decompensated heart failure
7.1 References
Appendix
Overview
Appendix I: Systematic literature review design and results
Appendix II: Revision history
Appendix III: Working group membership affiliations
2023 Update: Summary of changes to Recommendations
Executive Summary
Quick Reference Guide
Section 1: Background, aims and concise methods
1. Overview
1.1 Summary
1.2 Introduction
1.3 Molecular Mechanisms Of Action Of SGLT2I Inhibition
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
1.5 Guideline Aims & Development
1.6 References
Section 2: SGLT-2 inhibition and renal protection in people with CKD in the context of type 2 diabetes mellitus
2. Overview
2.1 Background
2.2 Recommendations For Use
2.3 Clinical Research Recommendations
2.4 Recommendations For Implementation
2.5 Audit Measures
2.6 References
Section 3: SGLT-2 inhibition and renal protection in people with CKD without diabetes mellitus
3. Overview
3.1 Background
3.2 Recommendations For Use
3.3 Clinical Research Recommendations
3.4 Recommendations for Implementation
3.5 Audit Measures
3.6 References
Section 4: Selection of SGLT-2 inhibitors
4. Overview
4.1 Background
4.2 Current Licensed Indications for SGLT-2 Inhibitor Use
4.3 References
Section 5: Prescribing SGLT-2 inhibitors safely
5. Overview
5.0 Background
5a. Diabetic ketoacidosis
5b. Hypoglycaemia
5c. Acute Kidney Injury, Hypovolaemia and Potassium
5d. Peripheral vascular disease and amputation risk
5e. Fracture risk
5f. Multimorbidity and frailty
5g. Mycotic genital infections and Fournier’s gangrene
5h. Urinary tract infections
5i. Children, pregnancy and breast feeding
5.1 References
Section 6: Lay summaries and patient information leaflets
6. Overview
6.0 Background
6.1 Lay Executive Summary
6.2 Full Summary of Guideline
6.3 Example Patient Information Sheet for a Person being Initiated on an SGLT-2 Inhibitor who also has Diabetes
6.4 Example Patient Information Sheet for a Patient being Initiated on an SGLT-2 Inhibitor who does not have Diabetes
Section 7: Use in special populations of specific interest
7. Overview
7a. Type 1 diabetes mellitus (DM)
7b. Kidney transplant recipients
7c. Acute decompensated heart failure
7.1 References
Appendix
Overview
Appendix I: Systematic literature review design and results
Appendix II: Revision history
Appendix III: Working group membership affiliations
Home
Section 1: Background, aims and concise methods
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
1.4 Table 1.1 Listing of large-scale placebo-controlled clinical outcome trials.
Prev: 1.3 Molecular Mechanisms Of Action Of SGLT2I Inhibition
Next: 1.5 Guideline Aims & Development
